As the pharma world turns its eyes to the American Society of Clinical Oncology meeting, the US Food and Drug Administration has at least eight novel oncology agents under review, according to data from the Pink Sheet’s US FDA Performance Tracker.
In terms of novel approvals, oncology has had a slow start in 2019. The approval of Novartis AG’s Piqray...